marker allows further investigation of the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively evaluated the association of the functional marker of vitamin B6 status, the 3-hydroxykynurenine:xanthurenic acid (HK:XA) ratio, with risk of lung cancer in a nested case-control study consisting of 5,364 matched case-control pairs from the Lung Cancer Cohort Consortium (LC3). We used conditional logistic regression to evaluate the association between HK:XA and lung cancer, and random effect models to combine results from different cohorts and regions. High levels of HK:XA, indicating impaired functional B6 status, were associated with an increased risk of lung cancer, the odds ratio comparing the fourth and the first quartiles (OR 4th vs. 1st ) was 1.25 (95% confidence interval, 1.10-1.41). Stratified analyses indicated that this association was primarily driven by cases diagnosed with squamous cell carcinoma. Notably, the risk associated with HK:XA was approximately 50% higher in groups with a high relative frequency of squamous cell carcinoma, i.e., men, former and current smokers. This risk of squamous cell carcinoma was present in both men and women regardless of smoking status.
Lung cancer is the most common cause of cancer related death, contributing to almost 20% of all cancer deaths worldwide. 1 The four major histological types of lung cancer are adenocarcinomas, squamous cell carcinomas, large cell carcinomas and small cell carcinomas. The most important risk factor for lung cancer is smoking, but the strength of the association depends on the type of lung cancer. 2 Some lung cancer types like small cell and squamous cell carcinomas occur almost exclusively due to smoking, while others, like adenocarcinomas, also occur frequently in nonsmokers. 2 Vitamin B6 may play a role in carcinogenesis, since it is involved in DNA synthesis, methylation, and repair, 3 chromosomal stability 4 and oxidative stress. 5 Indeed, circulating B6 measured as pyridoxal 5 0 -phosphate (PLP) was found to be inversely associated with lung cancer risk in two earlier case-control studies, nested in prospective cohorts, 6, 7 but in a recent analysis within the Lung Cancer Cohort Consortium (LC3), vitamin B6 was found to be only marginally associated with cancer risk in former and current smoking men. 8 However, circulating levels of the vitamin B6 measure used in these articles, the widely used PLP, are influenced by factors other than vitamin B6 status. These factors include inflammation, alkaline phosphatase activity, low serum albumin and renal function, 9 and reduce the usefulness of PLP as a marker of vitamin B6 status.
A recently established functional marker of vitamin B6 status is the ratio of circulating levels of two metabolites in the kynurenine pathway of tryptophan metabolism, 3-hydroxykynurenine (HK) and xanthurenic acid (XA), i.e., HK:XA. 4 The conversion of HK to XA is catalyzed by the PLP-dependent enzyme kynurenine aminotransferase, while the formation of HK does not require PLP. 10 The substrateproduct ratio HK:XA has been shown to increase in B6 deficient individuals and reduced to normal levels after supplementation with B6. 10 What's new? Low vitamin B6 status, assessed by circulating pyridoxal 5 0 -phosphate (PLP), has been associated with increased risk of lung cancer. Because PLP levels can be influenced by other parameters than vitamin B6 status, the authors analyzed a functional vitamin B6 marker, the hydroxykynurenine:xanthurenic acid ratio (HK:XA). They found that high levels of HK:XA, indicative of functional vitamin B6 impairment, was associated with increased risk of lung.
Given the drawbacks of PLP as a marker of vitamin B6 status, the aim of the present study was to use the functional vitamin B6 marker HK:XA to further investigate the role of vitamin B6 status as a predictor of lung cancer risk. The study used data from over 5,000 cases-controls pairs from the LC3, nested within 20 prospective cohorts from the United States, Europe, Asia and Australia.
Methods

Study population
All prospective cohort studies within the National Cancer Institute (NCI) Cancer Consortium were invited to participate in the study. Twenty cohorts, from the United States (11 cohorts), Europe (total of 4 cohorts from Norway, Sweden, and Finland), Asia (4 cohorts consisting of Chinese populations residing in Shanghai and Singapore) and Australia (1 cohort), fulfilled the inclusion criteria (having cryopreserved baseline plasma or serum samples, and being members of the US NCI Cohort Consortium in 2009) and accepted to participate. Details on design of the cohorts and their follow-up procedures have been previously published. 8 
Selection of cases and controls
Lung cancer cases were defined on the basis of the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) and included invasive cancers coded as C34.0-C34-9. From the 11,399 incident lung cancer cases with prediagnostic blood samples, 5,545 cases were selected by oversampling never and former smoking cases. For each case, one control was randomly chosen from risk-sets consisting of all cohort members alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were cohort, sex, date of blood collection and date of birth. Controls were also matched by smoking status at time of blood collection in five categories; never smokers, short-and long-term quitters among former smokers (<10 years, 10 years since quitting) and light and heavy smokers among current smokers (<15, 15 cigarettes per day). In total, 5,364 lung cancer case-control pairs were eligible for inclusion after excluding cases who were not correctly matched on smoking status (n 5 124), who had insufficient plasma sample volume for analysis of biomarkers (n 5 42) or had a revised date of diagnosis prior to blood draw (n 5 13). 8 
Biochemical analyses
Analysis of all serum or plasma samples was performed in the Bevital A/S laboratory (http://www.bevital.no) in Bergen, Norway. Concentrations of HK, XA, PLP and cotinine, a marker of recent nicotine exposure 11 were determined using a liquid chromatography-tandem MS assay, 12 and C-reactive protein (CRP) was analyzed by immuno-MALDI-MS 13 in batches of 86 samples. Quality control procedures included six calibration plasma, two control plasma and one blank sample (water) in each batch. All blood samples were stored at 2808C or lower until analysis and cases and their matched controls were analyzed together within the same batches in random order, with laboratory staff blinded to case-control status. Further details on the biochemical analyses have been published elsewere. 8 
Statistical analysis
We used conditional logistic regression (conditioning on individual case sets) to calculate the odds ratios (ORs) with 95% confidence intervals (CIs) for lung cancer according to levels of HK:XA. The analysis was adjusted for smoking intensity using quartiles of cotinine concentrations based on the distribution of cotinine among current smokers. We performed analyses within each cohort, comparing the fourth to the first quartile (OR 4th vs. 1st ) of HK:XA. Results were combined for each region (USA, Europe, Asia, Australia), and for the overall study population by using random effects models. Heterogeneity across subgroups was quantitatively assessed by the Q-test and I 2 index. 14 We further performed stratified analyses for sex, smoking category (never, former and current smokers), histology of lung cancer (by HK:XA tertiles) and time between blood sample collection and diagnosis. Due to the large differences in vitamin status between regions, 15 quartiles (or tertiles) of concentrations for each biomarker were based on the distribution among controls by region. We additionally used conditional logistic regression for calculating the OR for lung cancer across quartiles by region and for the total population, using the first quartile as reference. Quartiles were included as a continuous variable to calculate p for trend.
In supplementary analysis stratified by histology in addition to smoking status or sex we included HK:XA as a continuous variable, using the base-2 logarithm (log2) of the biomarker in a conditional logistic regression model. Estimates from this model may be interpreted as the relative risk associated with a doubling in circulating biomarker concentration. Partial Spearman correlations adjusted for age and sex were used to describe the association between HK:XA and PLP, and both biomarkers with cotinine. All statistical analyses were conducted using R 3.2.2 for Macintosh. 16 The package "survival" 17 was used for conditional logistic regression, and package "metafor" for forestplots. 18 
Results
Study population
The final study population included 5,364 lung cancer cases and 5,364 matched controls, with a median age of 62 years at blood sample collection (Table 1) . Median time between blood draw and lung cancer diagnosis was 6.3 years. Of the total study population, 46% of the participants were women. At baseline, nearly half of the participants were current smokers, and one fourth were former and never smokers, respectively ( 
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Theofylaktopoulou et al. Table 1 . Baseline and clinical characteristics of study participants overall and according to region Characteristics are presented as n (%) for discrete variables and median (5th, 95th percentile) for continuous variables. At blood collection. 
Study) included only men, and five cohorts (WHI, NYUWHS, WHS, NHS and SWHS) only women (Fig. 1) . The prevalence of smoking also differed substantially between cohorts (Fig. 1) .
Determinants of HK:XA within the LC3
HK:XA varied somewhat across regions, (median values ranging from 2.88 to 3.28 among controls) with the lowest level among Australian controls and the highest among Europeans. Larger variations were observed for plasma PLP, with the highest concentrations in the controls from US cohorts (median 49.9 nmol/L) and the lowest concentrations among the European cases, at 28.1 nmol/L. We observed an inverse relation between HK:XA and PLP (Spearman q 5 20.37), while smoking was essentially not associated with HK:XA (q 5 0.11) but was inversely related to plasma PLP (q 5 20.30); all p < 0.001.
HK:XA and lung cancer
Random effects models were used to investigate the relation of HK:XA with risk of lung cancer across geographic regions because the heterogeneity by cohort varied significantly across the geographic regions (Supporting Information Table  S1 ). Overall, high levels of HK:XA (fourth vs. first quartile) were associated with a 25% increased risk for lung cancer (Fig. 2) . However, results differed across regions with positive associations observed in Europe, with an OR comparing the fourth and the first quartiles (95% CI) of 1.43 (1.06, 1.95), and the United States 1.31 (1.05, 1.62), but no association in Asia or Australia (Fig. 2) . Results were similar when using quartiles based on the distribution of each region, instead of cohort specific cut-offs (Supporting Information Table S2 ). The weakest associations were observed in cohorts that included only women. When those cohorts (The Women's Health Initiative, The New York University Women's Health 
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Study, Women's Health Study and Nurses Health Study) were excluded, the association of HK:XA with risk of lung cancer in the United States was similar, 1.41 (1.15, 1.46), to that seen in Europe. Additional adjustment for CRP, a marker for systemic inflammation, did not attenuate the risk association for HK:XA (data not shown).
Analyses stratified by sex and smoking
In analysis stratified by sex, the overall association between HK:XA and lung cancer risk was primarily seen among men, with a 50% increased risk of lung cancer when comparing fourth versus first quartile (Fig. 3) . No significant association was observed for women, (p heterogeneity 5 0.01 and I 2 5 62.4%, Supporting Information Table S3 ). Smoking habits differed between sexes, with the proportion of never smokers much higher among women (Fig. 1) . A similar effect modification was present for smoking categories, with the association between HK:XA and lung cancer limited to current and former smokers (p for heterogeneity 5 0.18, I 2 5 30.1%, Supporting Information Table S4 ; Fig. 4 ).
Histology of lung cancer
Histology of lung cancer differed according to smoking status, with squamous cell carcinoma being more common Figure 2 . Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA Conditional logistic regression was performed for each cohort and was adjusted for smoking intensity using quartiles of cotinine among current smokers. Cases and controls were matched on age, sex, and smoking status. Results were combined using random effect models for each region and in all studies combined. HK:XA, 3-hydroxykynurenine:xanthurenic acid.
among current and former smokers (28% and 20%, respectively, compared to 6% among never smokers) and in men compared to women (29% vs. 10%). In analysis according to histology of lung cancer in the overall population, HK:XA was related to an increased risk for squamous cell carcinoma OR (95% CI) 1.42 (1.10, 1.82) for third versus first tertile, but not with other histological types (data not shown).
This association with HK:XA and squamous cell carcinoma was consistently present in subgroup analysis by both sex and smoking status. Specifically, for a continuous log2 model, representing a doubling of HK:XA concentrations, the OR (95% CI) was 1.20 (1.02, 1.41) in men, 1.59 (1.20, 2.10) in women (Supporting Information Fig. S2 ). In current smokers the OR (95% CI) was 1.22 (1.02, 1.46), in former smokers 1.37 (1.08, 1.73), and in never smokers 1.59 (0.90, 2.80), even though in this last group the CI was quite wide due to the low number of cases (Supporting Information  Fig. S1 ).
Time to diagnosis
In analysis stratified by time to diagnosis, the association was limited to participants who were diagnosed with lung cancer within 36 months from blood draw, OR log2 (95% CI) 1.43 (1.27, 1.61) for a doubling in the concentration of HK:XA. No significant association between HK:XA and lung cancer risk was observed for those with a longer time between blood draw and diagnosis (p for heterogeneity < 0.001).
Discussion
Main findings
High levels of HK:XA, indicating an impaired functional vitamin B6 status, were associated with an increased risk of lung cancer. In stratified analysis the risk of lung cancer was approximately 50% higher for those in the highest category of HK:XA in men, and in former and current smokers, but not significant in women or never smokers. In analysis stratified by histology HK:XA was associated with an increased risk of squamous cell carcinoma, but not other histological types. When histopathology subtype of lung cancer was considered, a consistent association was found for squamous cell carcinoma regardless sex and smoking status. The lack of association of HK:XA with overall lung cancer among women and never smokers could be at least partly attributed to the low number of cases of squamous cell carcinoma in those strata of the present study population.
Comparison with previous findings
Overall, our findings are in agreement with published results on the B6 vitamer PLP and cancer risk, 19 even though stronger inverse associations were noted in relation to lung cancer in the EPIC 6 and ATBC 7 studies. Concordant with the current study, we recently observed an inverse association of PLP with lung cancer risk in LC3, an association that was primarily confined to former and current smoking men. 8 We observed a positive association between HK:XA and risk of squamous cell carcinoma, but no significant association with other histological types of lung cancer. This Figure 3 . Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA in the different regions, stratified by gender. Conditional logistic regression was performed for each region and was adjusted for smoking intensity using quartiles of cotinine among current smokers. Cases and controls were matched on age, sex, and smoking status. Results were combined using random effect models. HK:XA, 3-hydroxykynurenine:xanthurenic acid.
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observation is also in line with a previous observation of an inverse association between plasma PLP and risk of cancer primarily classified as squamous cell carcinoma. 8 In EPIC, an inverse association of PLP on lung cancer was also observed in never smokers, but the number of cases that was never smokers was low (n 5 96), 6 and this results should be viewed with caution.
In a previous cohort study where PLP and HK:XA were simultaneously assessed as predictors of cancer, no clear association was found for any of the two markers. However, this study had limited statistical power due to the small number of cases (n cases 5 85).
20
HK:XA as a marker of vitamin B6 status and predictor of lung cancer
There are consistent reports on plasma PLP as a predictor of cancer in the lungs 6, 7 and other organs. 19 Plasma PLP is the most commonly used marker of vitamin B6 status, but plasma PLP concentrations are reduced by several factors linked to lung cancer carcinogenesis or progression, such as smoking, 21 inflammation measured as CRP [22] [23] [24] and increased level of alkaline phosphatase. 25 On the other hand, inflammation and elevated alkaline phosphatase (ALP) are not associated with impaired vitamin B6 availability in tissues. 9 Smoking is associated with lower levels of PLP, and vitamin B6 status gradually improves over years after smoking cessation. 26 In contrast, smoking shows no or a weak association with the HK:XA ratio, 10 an observation confirmed in the present study. In the current study, cases and controls were matched for smoking status and we additionally adjusted for smoking intensity, using circulating cotinine concentrations. We cannot exclude residual confounding by smoking, but since the association between HK:XA and lung cancer was also present in former smokers, confounding by smoking is unlikely.
CRP is inversely associated with plasma PLP 27,28 but shows a weak positive association with HK:XA. 10 After additional adjustment for CRP, the risk estimates of HK:XA and lung cancer remained essentially the same, suggesting no or minor confounding from inflammation. Elevated ALP may reduce PLP through conversion to pyridoxal (PL), 9 but HK and XA are not substrates for ALP, and one would not expect any direct effects from ALP on the plasma levels of these metabolites.
Similarly to the findings on PLP in the LC3 study, 8 the association between HK:XA and lung cancer was stronger among participants with a short time between blood draw and diagnoses.
Therefore, it is possible that the observed association between HK:XA and risk may reflect impaired vitamin B6 status due to preclinical changes in lung cancer. Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA in the different regions, stratified by smoking status. Conditional logistic regression was performed for each subgroup and among current smokers (adjusted for smoking intensity using quartiles of cotinine among current smokers). Cases and controls were matched for age, sex, and smoking status. Results were combined using random effect models. HK:XA, 3-hydroxykynurenine:xanthurenic acid.
Strengths and limitations of the study
The present study is based on a an unprecedented sample of 5,364 prediagnostic blood samples from lung cancer cases with comparable control samples recruited in 20 prospective cohorts from around the world. The prospective study design minimizes the risk of reverse causality and selection bias. The use of a centralized laboratory with stringent quality control protocols and cases and matched controls analyzed together minimizes any technical differential bias, and an overrepresentation of never and former smokers provided adequate power for stratified analysis. By using a functional marker that is largely independent on factors that are related to circulating PLP, we found a clear inverse relation of vitamin B6 status with risk of lung cancer.
There was only one blood sample available for measurement of biomarkers for each participant, so the association between HK:XA and lung cancer may be attenuated due to regression dilution bias. It is possible that depending on the time of the blood draw and the length of study follow-up, the single measurement may not represent the exposure period most relevant for lung cancer development. Lastly, information on the histology of lung cancer was missing for 34% of the participants.
Conclusions
Our findings provide evidence for an inverse association of functional vitamin B6 status and risk of lung cancer, especially squamous cell carcinoma. This expands our understanding beyond what can be concluded from the modest relation observed for the direct vitamin B6 marker PLP, 8 circulating levels of which is influenced by factors other than vitamin B6 status, in this same study. It is recommended that future studies strive for a sample size large enough to provide the power necessary for analysis stratified by duration of follow-up, smoking and histology given the potential differences of the role of vitamin B6 in pathogenesis and progression of different histological cancer types.
